CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
10561 ETCTN Rapid Analysis and Response Evaluation of Combination Anti-neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + Atezolizumab Adult CIRB - Early Phase Emphasis
10563 ETCTN A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin (Doxil®) in Patients with Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas Adult CIRB - Early Phase Emphasis
10572 ETCTN A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-related Inhibitor M1774 Adult CIRB - Early Phase Emphasis
10577 ETCTN Pilot Study of CBX-12 Pharmacodynamics in Patients with Advanced Solid Tumors Adult CIRB - Early Phase Emphasis
10579 ETCTN Phase I trial of ZEN003694 (ZEN-3694) in combination with capecitabine in patients with solid tumors Adult CIRB - Early Phase Emphasis
10590 ETCTN NORM: Nodular Lymphocyte-predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase 2 Trial with Either Rituximab or Mosunetuzumab Adult CIRB - Early Phase Emphasis
10592 ETCTN A Randomized Phase 2 Study of ATR inhibition in advanced PD-(L)1-refractory Merkel cell carcinoma: The MATRiX Trial Adult CIRB - Early Phase Emphasis
10596 ETCTN A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype with Higher-Risk Features or MLL/KMT2A Rearranged Disease Adult CIRB - Early Phase Emphasis
10597 ETCTN A Phase 1 Study of APG-1252 (pelcitoclax) and cobimetinib in recurrent ovarian and endometrial cancers Adult CIRB - Early Phase Emphasis
10601 ETCTN A Phase 1 Study of Mosunetuzumab with Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Adult CIRB - Early Phase Emphasis